| Identification | Back Directory | [Name]
Hexanedioic acid, compd. with 7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-[1-(4-piperidinyl)-1H-pyrazol-4-yl]thieno[3,2-d]pyrimidin-2-amine (1:2) | [CAS]
2388506-44-1 | [Synonyms]
Hexanedioic acid, compd. with 7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-[1-(4-piperidinyl)-1H-pyrazol-4-yl]thieno[3,2-d]pyrimidin-2-amine (1:2) | [Molecular Formula]
C28H33FN6O5S | [MOL File]
2388506-44-1.mol | [Molecular Weight]
584.67 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 25 mg/mL (42.76 mM; ultrasonic and warming and heat to 60°C)|DMF : 10 mg/mL (17.10 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032)[1]. | [Biological Activity]
MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032)[1]. | [storage]
Store at -20°C | [References]
[1]. Yuguang Wang, et al. Novel Therapeutic Methods. Patent WO2021180032A1. |
|
|